Rutgers Cancer Institute of New Jersey
195 Little Albany Street
New Brunswick, NJ 08903-2681
Statins are primarily prescribed for:
If you already have cardiovascular disease, your doctor may recommend statins to reduce your risk of having a heart attack or stroke. Statin therapy may also be prescribed if you fall within a specific risk range for developing cardiovascular disease within 10-years. The risk can be assessed based on your cholesterol numbers and other risk factors. It can be done during a regular physical exam.
HMG-CoA reductase is an enzyme that helps your body make cholesterol. Statins help to block this enzyme, which in turn causes your body to make less cholesterol. When you make less cholesterol, your liver makes more LDL receptors, which attract LDL particles in the blood. This reduces the amount of LDL ("bad") cholesterol in your bloodstream. Lower LDL cholesterol levels also tend to lead to lower levels of triglycerides and higher HDL (“good”) cholesterol levels in the blood. Statins have anti-inflammatory effects on blood vessels which help reduce the formation of fatty plaque on blood vessel walls.
Statins can interact with many medications. Below are some examples. But, you should talk to your doctor and pharmacist about the specific medications that you are taking.
Statins can interact with certain foods, herbs, and supplements. Here are examples of potential interactions:
If you would like to take herbs or supplements while taking a statin, check with your doctor first.
These conditions can affect how your body uses statins:
If you have any of the following conditions, tell your doctor before you are prescribed statins:
More common side effects include:
American Heart Association
US Food and Drug Administration
Heart & Stroke Foundation
Amarenco P, Bogousslavsky J, Callahan A 3rd, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355(6):549-559.
Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110(2):227-239.
Lemaitre RN, Psaty B, Heckbert SR, Kronmal RA, Newman AB, Burke GL. Therapy with hydroxymethylglutaryl coenzyme A reductase inhibitors (statins) and associated risk of incident cardiovascular events in older adults. Arch Intern Med. 2002;16(12)2:1395-1400.
Statins. EBSCO DynaMed Plus website. Available at:http://www.dynamed.com/topics/dmp~AN~T116844/Statins. Updated September 1, 2015. Accessed October 24, 2016.
Statins. Food and Drug Administration website. Available at: http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm294358.htm. Updated December 16, 2014. Accessed October 24, 2016.
Statin drugs. EBSCO Natural and Alternative Treatments website. Available at: http://www.ebscohost.com/biomedical-libraries/natural-alternative-treatments. Updated December 15, 2015. Accessed October 24, 2016.
Statins for prevention of cardiovascular disease. EBSCO DynaMed Plus website. Available at:http://www.dynamed.com/topics/dmp~AN~T115052/Statins-for-primary-and-secondary-prevention-of-cardiovascular-disease. Updated June 8, 2016. Accessed October 24, 2016.
Stender S, Schuster H, Barter P, Watkins C, Kallend D, MERCURY I Study Group. Comparison of rosuvastatin with atorvastatin, simvastatin, and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial. Diabetes Obes Metab. 2005;7(4):430-438.
Tahara N, Kai H, Ishibashi M, et al. Simvastatin attenuates plaque inflammation: evaluation by fuorodeoxyglucose positron emission tomography. J Am Coll Cardiol. 2006;48(9):1825-1831.
1/30/2009 DynaMed Plus Systematic Literature Surveillancehttp://www.dynamed.com/topics/dmp~AN~T115052/Statins-for-primary-and-secondary-prevention-of-cardiovascular-disease: Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, Perri D. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol. 2008;52(22):1769-1781.
Last reviewed October 2016 by Michael Woods, MD Last Updated: 10/24/2016